NCT01399840 is a Phase 1 clinical trial of BMN 673 in Acute Myeloid Leukemia, sponsored by Pfizer.

Who is sponsoring NCT01399840?

NCT01399840 is sponsored by Pfizer.

What drugs are being tested in NCT01399840?

Interventions in NCT01399840: BMN 673.

What condition does NCT01399840 study?

NCT01399840 studies Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma.

Is NCT01399840 still recruiting?

NCT01399840 is currently completed. Last updated 15 September 2017.

Last reviewed 2017-09-15 · How we verify

NCT01399840

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Completed Phase 1 Last updated 15 September 2017

What this trial tests

Phase 1 trial testing BMN 673 in Acute Myeloid Leukemia in 33 participants. Completed in 31 May 2014.

Timeline

30 June 2011

Primary endpoint
31 March 2014

31 May 2014

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	30 June 2011
Primary completion	31 March 2014
Estimated completion	31 May 2014
Sites	7 locations across United Kingdom, United States

Drugs / interventions tested

BMN 673 — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →
Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
Mantle Cell Lymphoma — all drugs for Mantle Cell Lymphoma →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with either AML or MDS; Arm 2 will enroll patients with either CLL or MCL.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting DNA damage response in cancer therapy.
Hosoya N, Miyagawa K. · · 2014 · cited 232× · PMID 24484288 · DOI 10.1111/cas.12366
Targeting DNA repair pathways for cancer treatment: what's new?
Kelley MR, Logsdon D, Fishel ML. · · 2014 · cited 143× · PMID 24947262 · DOI 10.2217/fon.14.60
Role of PARP inhibitors in cancer biology and therapy.
Davar D, Beumer JH, Hamieh L, Tawbi H. · · 2012 · cited 90× · PMID 22788767 · DOI 10.2174/092986712802002464
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A, Ghelli Luserna Di Rorà A, Marconi G, Ghetti M, et al · · 2022 · cited 73× · PMID 35065680 · DOI 10.1186/s13045-022-01228-0
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Gaymes TJ, Mohamedali AM, Patterson M, Matto N, et al · · 2013 · cited 54× · PMID 23349304 · DOI 10.3324/haematol.2012.079251
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. · · 2021 · cited 33× · PMID 34945003 · DOI 10.3390/cancers13246385
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Herriott A, Tudhope SJ, Junge G, Rodrigues N, et al · · 2015 · cited 27× · PMID 26539646 · DOI 10.18632/oncotarget.6287
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment.
Valikhani M, Rahimian E, Ahmadi SE, Chegeni R, et al · · 2021 · cited 20× · PMID 34732266 · DOI 10.1186/s40164-021-00242-1

Verify or expand the search:

Other trials of BMN 673

Trials testing the same drug.

NCT02316834 — Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Pri · EARLY_PHASE1 · completed
NCT02127151 — A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer · Phase 2 · withdrawn
NCT01989546 — Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations · Phase 1, PHASE2 · completed

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01399840 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 15 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01399840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing